Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report. (18th December 2018)

• Record Type: Journal Article
• Authors: Barnhoorn, Marieke C; Van Halteren, Astrid G S; Van Pel, Melissa; Molendijk, Ilse; Struijk, Ada C; Jansen, Patty M; Verspaget, Hein W; Dijkstra, Gerard; Oosten, Liesbeth E M; Van der Meulen – de Jong, Andrea E
• Is Part Of: Journal of Crohn's and colitis. Volume 13:Number 6(2019)
• Page Start: 807
• Page End: 811
• Publication Date: 2018-12-18
• Subjects: perianal fistulas -- Crohn's disease -- mesenchymal stromal cells -- lymphoproliferative disease; Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjy220
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Mesenchymal stromal cell [MSC] therapy is a new treatment for perianal fistulas in Crohn's disease. Although MSC therapy shows a favourable safety profile, long-term safety data are limited. We detected an Epstein Barr virus [EBV]-associated B cell lymphoproliferative lesion in the rectum of a patient 4 years after local administration of MSCs for his perianal fistulas. To investigate whether MSC therapy contributed to the development of this lymphoproliferative disease, we analyzed the possibility of EBV transfer via the MSC product and the persistence of MSCs in the lymphoproliferative lesion using short tandem repeat analysis.